title: CD34-derived human Langerhans cells stimulate a T helper type 2 response independently of extracellular-signal-regulated kinase phosphorylation.
abstract: Dendritic cell (DC) subsets can mediate diverse responses, but little is known about the Toll-like receptor (TLR) signalling pathways in different human DC subsets. Despite expressing many TLRs in common, we found that in vitro-derived Langerhans cells (LCs) and monocyte-derived DCs (moDCs) undergo differential signalling events following TLR stimulation. TLR-stimulated LCs did not secrete interleukin (IL)-12p70 and thus induced a T helper type 2 (Th2)-biased response. moDCs secrete high levels of IL-12p70 and induce a Th1 response. Stimulation of moDCs through TLR2 or TLR7/8 was able to induce phosphorylation of the mitogen-activated protein kinase (MAPK) extracellular-signal-regulated kinase (ERK). However, phosphorylated ERK was not induced in TLR-stimulated LCs, suggesting an ERK-independent method of Th2 cell induction. Inhibition of p38 MAPK suppressed moDC maturation, but was much less effective at inhibiting LC maturation. Phosphatidylinositol-3 kinase (PI3K) was also found to play a greater role in moDC survival compared with the LCs. Polymerase chain reaction (PCR) arrays to compare the expression of signalling molecules in LCs and moDCs identified differences in TLR recognition molecules and cytokine response genes, suggesting that differential functional responses are probably mediated at the post-transcriptional level. Thus we have described differences in LC and moDC responses to TLR stimulation, and have identified key differences in ERK phosphorylation and the involvement of MAPK and PI3K.
authors.affiliation: Department of Immunology, Faculty of Medicine, Imperial College, Chelsea and Westminster Hospital, London, UK.
authors.forename: Sai S
authors.initials: SS
authors.lastname: Duraisingham
authors.forename: Julia
authors.initials: J
authors.lastname: Hornig
authors.forename: Frances
authors.initials: F
authors.lastname: Gotch
authors.forename: Steven
authors.initials: S
authors.lastname: Patterson
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D018952:Antigens, CD34 / Q000378:metabolism*; D051940:B7-2 Antigen / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects / Q000276:immunology; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015870:Gene Expression / Q000187:drug effects / Q000235:genetics; D006684:HLA-DR Antigens / Q000378:metabolism; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000378:metabolism; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D007371:Interferon-gamma / Q000378:metabolism / Q000494:pharmacology; D018664:Interleukin-12 / Q000378:metabolism; D053762:Interleukin-12 Subunit p40 / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics; D007801:Langerhans Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism*; D008213:Lymphocyte Activation / Q000276:immunology*; D007959:Lymphocyte Culture Test, Mixed; D008562:Membrane Glycoproteins / Q000378:metabolism; D019950:Mitogen-Activated Protein Kinase 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000037:antagonists & inhibitors / Q000378:metabolism; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D009000:Monocytes / Q000166:cytology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D018417:Th1 Cells / Q000276:immunology / Q000378:metabolism; D018418:Th2 Cells / Q000276:immunology* / Q000378:metabolism; D051193:Toll-Like Receptors / Q000819:agonists; D000097802:CD83 Antigen
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D051940:B7-2 Antigen; D048049:Extracellular Signal-Regulated MAP Kinases; D006684:HLA-DR Antigens; D007136:Immunoglobulins; D007371:Interferon-gamma; D018664:Interleukin-12; D053762:Interleukin-12 Subunit p40; D015847:Interleukin-4; D047908:Intracellular Signaling Peptides and Proteins; D008562:Membrane Glycoproteins; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases; D019869:Phosphatidylinositol 3-Kinases; D051193:Toll-Like Receptors; D000097802:CD83 Antigen; C497964:CD86 protein, human; C508598:IL4 protein, human; C535150:MAPK1 protein, human
references.citation: Nat Rev Immunol. 2003 Feb;3(2):133-46
references.pmid: 12563297
references.citation: Nature. 1998 Mar 19;392(6673):245-52
references.pmid: 9521319
references.citation: Clin Exp Dermatol. 2000 Jul;25(5):413-8
references.pmid: 11012599
references.citation: Annu Rev Immunol. 2003;21:335-76
references.pmid: 12524386
references.citation: Blood. 2000 Aug 1;96(3):1039-46
references.pmid: 10910920
references.citation: J Dermatol Sci. 2006 Aug;43(2):152-5
references.pmid: 16716569
references.citation: J Immunol. 2001 Mar 15;166(6):3837-45
references.pmid: 11238627
references.citation: J Immunol. 2006 Dec 1;177(11):7959-67
references.pmid: 17114468
references.citation: Int Immunol. 2004 Dec;16(12):1701-9
references.pmid: 15477228
references.citation: J Dermatol. 2007 Jun;34(6):403-6
references.pmid: 17535410
references.citation: J Immunol. 2009 Aug 15;183(4):2242-51
references.pmid: 19625644
references.citation: J Immunol. 2003 Nov 15;171(10):4984-9
references.pmid: 14607893
references.citation: J Immunol. 2005 Dec 15;175(12):7905-15
references.pmid: 16339526
references.citation: Nature. 1997 Aug 21;388(6644):782-7
references.pmid: 9285591
references.citation: Blood. 2000 Dec 15;96(13):4276-84
references.pmid: 11110702
references.citation: Blood. 2001 Oct 1;98(7):2175-82
references.pmid: 11568005
references.citation: Immunity. 2007 Apr;26(4):519-31
references.pmid: 17412618
references.citation: J Immunol. 2004 Aug 15;173(4):2780-91
references.pmid: 15294997
references.citation: J Infect Dis. 2008 Dec 15;198(12):1823-33
references.pmid: 18945182
references.citation: J Exp Med. 1998 Dec 7;188(11):2175-80
references.pmid: 9841930
references.citation: J Exp Med. 1994 Oct 1;180(4):1263-72
references.pmid: 7523569
references.citation: Nat Immunol. 2005 Jun;6(6):571-8
references.pmid: 15852007
references.citation: J Immunol. 2005 Jun 15;174(12):8200-9
references.pmid: 15944329
references.citation: Int Immunol. 2009 Apr;21(4):317-37
references.pmid: 19246554
references.citation: Immunity. 2007 Oct;27(4):610-24
references.pmid: 17936032
references.citation: J Dermatol Sci. 2006 Apr;42(1):1-11
references.pmid: 16352421
references.citation: Immunity. 2008 Sep 19;29(3):497-510
references.pmid: 18789730
references.citation: Immunology. 2008 Jul;124(3):329-38
references.pmid: 18194273
references.citation: J Exp Med. 2008 Feb 18;205(2):315-22
references.pmid: 18227218
references.citation: Biol Pharm Bull. 2007 Sep;30(9):1617-23
references.pmid: 17827709
references.citation: Nat Rev Immunol. 2004 Jul;4(7):499-511
references.pmid: 15229469
references.citation: Nat Immunol. 2002 Jul;3(7):667-72
references.pmid: 12055629
references.citation: J Immunol. 2007 Feb 15;178(4):1986-90
references.pmid: 17277101